Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Caribou Biosciences (CRBU) EPS (Weighted Average and Diluted) (2021 - 2025)

Caribou Biosciences (CRBU) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.28 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 28.21% to -$0.28 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.59 through Dec 2025, up 3.64% year-over-year, with the annual reading at -$1.59 for FY2025, 3.64% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.28 at Caribou Biosciences, up from -$0.3 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.09 in Q4 2021, with the low at -$1.39 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.43, with a median of -$0.43 recorded in 2025.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 600.0% in 2022, then soared 72.73% in 2023.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at $0.09 in 2021, then plummeted by 600.0% to -$0.45 in 2022, then grew by 11.11% to -$0.4 in 2023, then grew by 2.5% to -$0.39 in 2024, then grew by 28.21% to -$0.28 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.28, -$0.3, and -$0.58 for Q4 2025, Q3 2025, and Q2 2025 respectively.